Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). (Q38246994)

1 September 2017

1 reference

title

Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). (English)

1 reference

mucopolysaccharidosis type IVA

1 September 2017

1 reference

based on heuristic

inferred from title

author

Katherine A Lyseng-Williamson

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

1 September 2017

1 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

28

1 reference

1 September 2017

5

1 reference

1 September 2017

465-475

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-014-0108-z

1 September 2017

0 references

cites work

International Morquio A Registry: clinical manifestation and natural course of Morquio A disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Diagnosing mucopolysaccharidosis IVA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Incidence of the mucopolysaccharidoses in Northern Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Incidence of inborn errors of metabolism in British Columbia, 1969-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The frequency of lysosomal storage diseases in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Prevalence of lysosomal storage diseases in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The Structure of Human GALNS Reveals the Molecular Basis for Mucopolysaccharidosis IV A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Orthopedic management of the extremities in patients with Morquio A syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Intellectual and neurological functioning in Morquio syndrome (MPS IVa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0108-Z

10.1007/S40259-014-0108-Z

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25200032